ライフサイエンスコーパス: lipodystrophy

1 fat excess (overweight/obesity) or fat loss (lipodystrophy).

2 ile consistent with a common, subtle form of lipodystrophy.

3 se ob/ob background accelerated the onset of lipodystrophy.

4 ribe a family with MPGN and acquired partial lipodystrophy.

5 describe here a unique mouse model of severe lipodystrophy.

6 in-resistant patients with hyperglycemia and lipodystrophy.

7 ies that have been utilized in patients with lipodystrophy.

8 whereby pathogenic mutations in BSCL2 cause lipodystrophy.

9 their EHR for comorbidities associated with lipodystrophy.

10 respect to dyslipidemia, hyperglycemia, and lipodystrophy.

11 otypes, providing a mouse model of inducible lipodystrophy.

12 fat have a phenotype reminiscent of partial lipodystrophy.

13 short-term overfeeding in patients with HIV lipodystrophy.

14 hy, or later in life, as in familial partial lipodystrophy.

15 cations for anti-obesity medical therapy and lipodystrophy.

16 iabetes, obesity, cancer, and HIV-associated lipodystrophy.

17 zed by dyslipidemia, insulin resistance, and lipodystrophy.

18 sed levels of IGF-1 in HIV-infected men with lipodystrophy.

19 men with human immunodeficiency virus (HIV) lipodystrophy.

20 sociated with better lipid profiles and less lipodystrophy.

21 cles, acro-osteolysis, cutaneous atrophy and lipodystrophy.

22 ked to the insulin resistance of obesity and lipodystrophy.

23 NA associated with Dunnigan familial partial lipodystrophy.

24 en reported in patients with MAD and partial lipodystrophy.

25 ed with progeroid appearance and generalized lipodystrophy.

26 ssociated hepatic steatosis in patients with lipodystrophy.

27 minant of accelerated IR without evidence of lipodystrophy.

28 tabolic abnormalities associated with severe lipodystrophy.

29 ment, and provide a candidate gene for human lipodystrophy.

30 isk parameters in HIV-infected patients with lipodystrophy.

31 None of the subjects exhibited clinical lipodystrophy.

32 cronemia syndrome (FCS); or familial partial lipodystrophy.

33 d its mutations cause congenital generalized lipodystrophy.

34 en characterized as an idiopathic subtype of lipodystrophy.

35 ponsible for the development of diabetes and lipodystrophy.

36 uman ARL15 haploinsufficiency predisposes to lipodystrophy.

37 tutively low leptin levels, such as occur in lipodystrophy.

38 lipodystrophy, Berardinelli-Seip congenital lipodystrophy.

39 This may explain WZB117-induced murine lipodystrophy.

40 cells from progeroid INK-ATTAC mice prevents lipodystrophy.

41 have therapeutic applications in obesity or lipodystrophy.

42 , an aged appearance, and severe generalized lipodystrophy.

43 al link between this process and HIV-related lipodystrophy.

44 dating the molecular basis of many inherited lipodystrophies.

45 enesis and maintenance and the cause of some lipodystrophies.

46 sms underlying dyslipidemia in patients with lipodystrophies.

47 2), have been found in patients with genetic lipodystrophies.

48 by dyslipidemia and fatty liver, as seen in lipodystrophies.

49 nt of fat loss also varies among subtypes of lipodystrophies.

50 of body fat is the hallmark of patients with lipodystrophies.

51 Seipin, a conserved protein often mutated in lipodystrophies.

52 K2) could also be a candidate gene for other lipodystrophies.

53 erquartile range 0.1%-0.5%]), in contrast to lipodystrophy (10.6% [interquartile range 2.8%-17.1%], P

54 ltransferase 2, Berardinelli-Seip congenital lipodystrophy 2, caveolin 1, lamin A/C, peroxisome proli

55 dystrophy (8 patients) or Dunnigan's partial lipodystrophy (2 patients) were included in this analysi

56 as significantly higher in patients with HIV lipodystrophy [33.2 +/- 0.27 kcal/kg lean body mass (LBM

57 Ten patients with either generalized lipodystrophy (8 patients) or Dunnigan's partial lipodys

58 tin is an approved treatment for generalized lipodystrophy, a condition associated with severe metabo

59 People with lipodystrophy, a disorder characterized by particularly

60 dystrophy (fld) gene have features of human lipodystrophy, a genetically heterogeneous group of diso

61 ncoding lamin A/C) underlie familial partial lipodystrophy, a syndrome of monogenic insulin resistanc

62 In contrast, in monogenic primary lipodystrophy-a reduction in subcutaneous adipose tissue

63 Additionally, lipodystrophy, acquired from the standard highly active

64 Acquired generalized lipodystrophy (AGL) is a rare condition characterized by

65 A lipodystrophy allele of seip-1 resulted in embryonic let

66 identify variants associated with inherited lipodystrophies and examined their EHR for comorbidities

67 of autosomal recessive and dominant types of lipodystrophies and therapeutic interventions available

68 lice site mutation in a proband with partial lipodystrophy and a history of childhood yolk sac tumour

69 ity and type 2 diabetes mellitus, as well as lipodystrophy and aging.

70 e unique combination of acquired generalized lipodystrophy and Crohn's disease (AGLCD) featuring a la

71 y associated with metabolic diseases such as lipodystrophy and diabetes.

72 ouse model (fatless AZIP/F-1 mice) of severe lipodystrophy and diabetes.

73 hronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE syndrome)

74 hronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature (CANDLE) is a rar

75 hronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), which i

76 nant-negative mutations in PPARgamma display lipodystrophy and extreme insulin resistance.

77 1 in the mouse, but not in humans, leads to lipodystrophy and fatty liver disease.

78 dystrophy (fld) mice, which exhibit partial lipodystrophy and have diminished peripheral adipose sto

79 protease inhibitor therapy adversely induces lipodystrophy and hyperlipidemia has not been defined.

80 ceiving protease inhibitors develop a marked lipodystrophy and hyperlipidemia.

81 example, mutations in PPARG cause Mendelian lipodystrophy and increase risk of type 2 diabetes (T2D)

82 , making the A-ZIP/F-1 mice a good model for lipodystrophy and insulin resistance.

83 aneously by 1 year of age, despite sustained lipodystrophy and insulin resistance.

84 tions in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general pop

85 PPARgamma inactivation caused severe lipodystrophy and insulin resistance; surprisingly, it a

86 re of human and rodent models of generalized lipodystrophy and is also a common feature of type 2 dia

87 ides a conditional animal model for studying lipodystrophy and its associated physiology and gene exp

88 ever, the mechanisms for how alcohol induces lipodystrophy and its impact on liver steatosis and inju

89 leptin for the treatment of individuals with lipodystrophy and leptin deficiency is well established.

90 creased triglyceride levels in patients with lipodystrophy and leptin deficiency.

91 ytes undergo dedifferentiation that leads to lipodystrophy and metabolic dysfunction.

92 with adverse side effects, including partial lipodystrophy and metabolic syndrome.

93 lethal combination of pathologies, including lipodystrophy and multiple hemorrhages.

94 nse mutation in a proband with femorogluteal lipodystrophy and non classical congenital adrenal hyper

95 Lipodystrophy and obesity are opposites in terms of a de

96 ed that adipose tissue macrophages (ATMs) in lipodystrophy and obesity are very different in terms of

97 s an accumulation of prelamin A and leads to lipodystrophy and other disease phenotypes.

98 HIV lipodystrophy and other lipodystrophy syndromes are char

99 atment for HIV but have been associated with lipodystrophy and other side effects.

100 o suggest and prioritize candidate genes for lipodystrophy and related disorders.

101 years; eight with diabetes mellitus) who had lipodystrophy and serum leptin levels of less than 4 ng

102 monogenic diabetic syndromes and congenital lipodystrophies, and candidate gene association studies

103 lude muscular dystrophies, cardiomyopathies, lipodystrophies, and premature aging syndromes.

104 ulin resistance in obesity, type 2 diabetes, lipodystrophy, and ageing; and the insulin-sensitising e

105 ders, including obesity, metabolic syndrome, lipodystrophy, and cachexia.

106 immunodeficiency, endocrine insufficiencies, lipodystrophy, and cancer predisposition.

107 rder characterized by short stature, partial lipodystrophy, and insulin resistance.

108 including markedly aberrant fuel metabolism, lipodystrophy, and muscular dystrophy.

109 ee genetic diseases: HVDRR, congenital total lipodystrophy, and persistent mullerian duct syndrome.

110 g, obesity, Cushing's syndrome, and acquired lipodystrophy, and preliminary evidence suggests that ec

111 ncluding muscular dystrophy, cardiomyopathy, lipodystrophy, and progeria, but mutations in B-type lam

112 uman diseases, including muscular dystrophy, lipodystrophy, and progeria, but no diseases have been l

113 muscular dystrophy, cardiomyopathy, partial lipodystrophy, and progeroid syndromes.

114 muscular dystrophy, cardiomyopathy, partial lipodystrophy, and progeroid syndromes.

115 (-/-) mice were lean, demonstrated abdominal lipodystrophy, and remained insulin-sensitive despite ha

116 es, which include premature aging syndromes, lipodystrophy, and striated muscle disorders.

117 reduction in body weight and length, partial lipodystrophy, and systemic insulin resistance.

118 most cases of NAFLD associated with obesity, lipodystrophy, and type 2 diabetes.

119 In contrast, lipodystrophy (aP2-SREBP-1c436) and liver X receptor act

120 In this population, the lipodystrophy appears to be a direct consequence of drug

121 Lipodystrophies are a group of disorders characterized b

122 The lipodystrophies are a group of disorders characterized b

123 Inherited lipodystrophies are an important cause for monogenic hyp

124 Lipodystrophies are characterized by a loss of white adi

125 Inherited lipodystrophies are rare autosomal recessive and dominan

126 Lipodystrophies are rare inherited and acquired disorder

127 Lipodystrophies are syndromes of adipose tissue degenera

128 Lipodystrophies are the result of a range of inherited a

129 ein cholesterol, higher body-mass index, and lipodystrophy are potentially modifiable risk factors as

130 Panniculitis and lipodystrophy are rare disorders of subcutaneous tissue.

131 The aramchol for HIV-associated NAFLD and lipodystrophy (ARRIVE) trial was a double-blind, randomi

132 podystrophy was hypertensive, ruling out the lipodystrophy as a cause.

133 A cause laminopathies, which include partial lipodystrophies associated with metabolic syndromes.

134 2) describe a stereotyped pattern of partial lipodystrophy associated with all the features of the me

135 L) type 2 (BSCL2; also known as seipin) is a lipodystrophy-associated endoplasmic reticulum membrane

136 ling agents as a potential novel therapy for lipodystrophy-associated hypertriglyceridemia, NASH and

137 The lipodystrophy-associated LMNA p.R482W mutation is known

138 These findings distinguish myopathy- and lipodystrophy-associated mutations and provide a structu

139 We observed a lipodystrophy-associated variant carrier frequency of 1

140 Skin analyses in other models of lipodystrophy, AZIP(tg/+) and Adipoq-Cre(tg/+)Pparg(fl/f

141 A case definition for HIV lipodystrophy, based on age, gender, duration of HIV dis

142 sis, suggesting that neither strain develops lipodystrophy because of defective adipocyte differentia

143 the most common form of autosomal recessive lipodystrophy, Berardinelli-Seip congenital lipodystroph

144 the context of Berardinelli-Seip congenital lipodystrophy (BSCL) linked to seipin deficiency.

145 Berardinelli-Seip congenital lipodystrophy (BSCL) type 2 (BSCL2; also known as seipin

146 increased significantly in patients with HIV lipodystrophy but not in the control groups (33.2 +/- 0.

147 improving metabolic control in patients with lipodystrophy, but its efficacy has not been tested in o

148 obesity, type 2 diabetes, and some forms of lipodystrophy, but whether this dysfunction contributes

149 es steatosis of hypoleptinemic patients with lipodystrophy by an unknown mechanism.

150 s in AGPAT2 may cause congenital generalized lipodystrophy by inhibiting triacylglycerol synthesis an

151 be attuned to the psychological impact that lipodystrophy can have on patients, especially because i

152 estimating the pathogenesis of human partial lipodystrophy caused by CIDEC mutations.

153 garding the molecular pathogenesis of severe lipodystrophy caused by mutations in either seipin or AG

154 iciency causes severe congenital generalized lipodystrophy (CGL) and metabolic disease.

155 Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disord

156 Congenital generalized lipodystrophy (CGL) is a rare disorder characterized by

157 ny of the features of congenital generalized lipodystrophy (CGL), an autosomal recessive disorder in

158 Congenital generalized lipodystrophy (CGL), secondary to AGPAT2 mutation is cha

159 viduals affected with congenital generalized lipodystrophy (CGL).

160 A syndrome of lipodystrophy, characterized by fat redistribution and i

161 Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss (l

162 The familial partial Dunnigan lipodystrophy, characterized by subcutaneous fat loss, i

163 e biology and suggested that subtle forms of lipodystrophy contribute to cardiometabolic disease risk

164 f fatty liver disease using a mouse model of lipodystrophy created by a fat-specific knockout of the

165 an association with calcinosis and p155 with lipodystrophy), cytokine polymorphisms, which appear to

166 tisystem disorder that includes subcutaneous lipodystrophy, deafness, mandibular hypoplasia and hypog

167 nts with a novel subtype of familial partial lipodystrophy, designated as FPLD4.

168 tant regulator of metabolism associated with lipodystrophy, diabetes, and hepatic steatosis.

169 These mice develop severe lipodystrophy, diabetes, hyperlipidemia, and fatty liver

170 adults from the Geisinger Health System for lipodystrophy diagnostic codes.

171 luate the clinical and genetic prevalence of lipodystrophy disorders in a large clinical care cohort.

172 Familial partial lipodystrophy, Dunnigan variety, (FPLD, OMIM 308980) is

173 Metabolic disorders, including lipodystrophy, dyslipidemia, and insulin resistance, occ

174 Patients with lipodystrophy exhibit hypertriglyceridemia, severe insul

175 yme Dicer (ADicerKO), as well as humans with lipodystrophy, exhibit a substantial decrease in levels

176 , fat samples from patients with HIV-related lipodystrophy exhibited a substantial downregulation of

177 Among genetic lipodystrophies, fat loss is observed either from birth,

178 Lipin deficiency causes lipodystrophy, fatty liver, and insulin resistance in mi

179 Familial partial lipodystrophy (FPLD), Dunnigan variety, is an autosomal

180 cle defects, and the other, familial partial lipodystrophy (FPLD), involves loss of subcutaneous adip

181 idues genetically linked to familial partial lipodystrophy (FPLD).

182 dystrophy and Dunnigan-type familial partial lipodystrophy (FPLD).

183 s of muscular dystrophy and familial partial lipodystrophy (FPLD).

184 understanding of the biologic role of these lipodystrophy genes.

185 The term 'HIV/HAART associated dyslipidemic lipodystrophy (HADL)' describes this syndrome.

186 the molecular pathophysiology of congenital lipodystrophies has yielded useful insights into the bio

187 Recently the incidence of lipodystrophy has been increasing secondary to its appea

188 netic studies in hyperglycemic patients with lipodystrophies have revealed accelerated lipolysis and

189 scribe a metabolic disorder characterized by lipodystrophy, hepatic steatosis, insulin resistance, se

190 n production, severe hyperglycemia/diabetes, lipodystrophy, hepatosteatosis, and growth retardation.

191 ed with several metabolic changes, including lipodystrophy, hyperlipidemia, and insulin resistance.

192 metabolic side effects, including peripheral lipodystrophy, hyperlipidemia, insulin resistance, and i

193 ndrome that resembles congenital generalized lipodystrophy in humans.

194 d adipocyte differentiation as the basis for lipodystrophy in lipin-deficient mice and demonstrate th

195 Lipin-1 mutations cause lipodystrophy in mice and acute myopathy in humans.

196 ted allele that confers conditional dominant lipodystrophy in mice.

197 ents to treat the different features seen in lipodystrophy in order to reduce their long-term cardiov

198 The apparent partial lipodystrophy in Reep1 null mice, although less severe,

199 Both physician and patient rating of lipodystrophy in the arms, legs, and abdomen also improv

200 tes is functionally required for Wnt-induced lipodystrophy in the DWAT and fibrotic remodeling.

201 the Lpin1 (lipin) gene to be responsible for lipodystrophy in the fatty liver dystrophy (fld) mouse s

202 ns in the lipin gene, Lpin1, as the cause of lipodystrophy in the fatty liver dystrophy (fld) mouse.

203 encoding lipin-1, as the underlying cause of lipodystrophy in the fatty liver dystrophy (fld) mutant

204 nzymes and explain the biochemical basis for lipodystrophy in the lipin-1-deficient fld mouse.

205 ia, and panniculitis-induced childhood-onset lipodystrophy) in adults.

206 sulin resistance, but their contributions to lipodystrophy-induced insulin resistance have not been e

207 Unexpectedly, tTA elicits mild lipodystrophy, insulin resistance, and dyslipidemia, and

208 Lipodystrophy is a disorder characterized by a loss of a

209 Lipodystrophy is a rare disorder characterized by comple

210 Lipodystrophy is a rare disorder that is characterized b

211 Congenital generalized lipodystrophy is an autosomal recessive disorder charact

212 Partial lipodystrophy is an underdiagnosed condition.

213 Since severe lipodystrophy is associated with leptin deficiency, insu

214 Berardinelli-Seip lipodystrophy is caused by autosomal recessive mutations

215 Severe lipodystrophy is characterized by diminished adipose tis

216 Lipodystrophy is characterized by the complete or partia

217 Acquired lipodystrophy is often characterized as an idiopathic su

218 hown in family members with acquired partial lipodystrophy, it did not segregate with the renal pheno

219 microcytic anemia, and panniculitis-induced lipodystrophy (JMP).

220 Lipodystrophy (LD) is a rare disease with a paucity of s

221 tus (T2DM) in HIV+ patients with and without lipodystrophy (LD+ and LD-, respectively) during a 16-ye

222 hout late failure of insulin production, and lipodystrophy leading to ectopic lipid accumulation in t

223 cted individuals may develop malnutrition or lipodystrophy, leading to losses of subcutaneous adipose

224 patients with extreme insulin resistance and lipodystrophy, leptin ameliorates insulin resistance, hy

225 white and brown adipose tissue resulted in a lipodystrophy-like syndrome.

226 e adipose mass and function, giving rise to "lipodystrophy-like" insulin resistance.

227 noted were hepatitis, peripheral neuropathy, lipodystrophy/lipoatrophy, and pancreatitis, whereas the

228 us, raising the possibility of more than two lipodystrophy loci within the Oman population.

229 encoding proteins known to activate lipin, a lipodystrophy locus in mice, and 16 other genes that are

230 Lipin 2 (LPIN2), a candidate gene for lipodystrophy, maps in proximity to this locus.

231 y of dyslipidemia in these rare disorders of lipodystrophies may offer insights into the normal role

232 ther research is needed to determine whether lipodystrophy may be misdiagnosed as wasting syndrome.

233 lipidemia, insulin resistance, hypoglycemia, lipodystrophy, motor-neuron death, and hepatitis C infec

234 orders of liporegulation include generalized lipodystrophies, mutations of leptin and leptin receptor

235 gulation, and mutations in these genes cause lipodystrophy, myoglobinuria, and inflammatory disorders

236 pecific phenotypes including cardiomyopathy, lipodystrophy, myopathy, neuropathy, progeria, bone/skin

237 E was measured in HIV-infected patients with lipodystrophy (n = 9) and in HIV-infected (n = 10) and h

238 = 7) versus postreceptor IR that was severe (lipodystrophy, n = 14), moderate (type 2 diabetes, n = 9

239 ange of human disorders, including progeria, lipodystrophy, neuropathies and autosomal dominant Emery

240 However, that mouse model is confounded by lipodystrophy not phenocopied in people.

241 ose tissue, and adipocyte dysfunction causes lipodystrophy, obesity and diabetes.

242 ts in the context of human linkage scans for lipodystrophy, obesity, and type 2 diabetes.

243 racellular matrix (ECM) and dermal adipocyte lipodystrophy occurs during skin fibrosis, which comprom

244 3Cys) was found in a patient with congenital lipodystrophy of unknown cause.

245 FIT2 (AF2KO) in mice results in progressive lipodystrophy of white adipose depots and metabolic dysf

246 ons cause axonal neuropathy, with associated lipodystrophy only occasionally noted, however homozygos

247 Lipodystrophy or fat re-distribution, and its associated

248 CI, 1.13-1.49]; P<.001), and the presence of lipodystrophy (OR, 3.82 [95% CI, 1.13-12.88]; P=.03).

249 In mice with too little fat (lipodystrophy) or too much fat (ob/ob), leptin deficienc

250 issense mutation in human seipin that causes lipodystrophy, or corresponding mutations in the yeast g

251 her from birth, as in congenital generalized lipodystrophy, or later in life, as in familial partial

252 riptional role of PTRF not only explains the lipodystrophy phenotype observed in PTRF deficient mice

253 Partial lipodystrophy (PLD; MIM 151660) is an inherited conditio

254 Clinical severity, epilepsy, and lipodystrophy predicted greater response.

255 The lipodystrophy protein SEIPIN is important for lipid drop

256 The prevalence of HIV-associated lipodystrophy ranges from 6% to 69% in the medical liter

257 -ray absorptiometry and computed tomography, lipodystrophy ratings, and levels of glucose, insulin, a

258 uman immunodeficiency virus (HIV)-associated lipodystrophy refers to fat accumulation, also known as

259 iver is a common feature of both obesity and lipodystrophy, reflecting compromised adipose tissue fun

260 Loss of adipose tissue, or lipodystrophy, results in hyperinsulinemia, diabetes mel

261 henotypes, such as short lifespan, dwarfism, lipodystrophy, sarcopenia, and low cardiac stress tolera

262 d with a similar phenotype including partial lipodystrophy, severe insulin resistance and type 2 diab

263 Both patients also had lipodystrophy, severe insulin resistance, and diabetes,

264 cause three distinct pathologies in humans: lipodystrophy, spondylometaphyseal dysplasia with cone-r

265 HIV lipodystrophy syndrome (HLS) is characterized by acceler

266 lycerolemia, a characteristic feature of HIV lipodystrophy syndrome (HLS), is incompletely understood

267 tprandial period may be a feature of the HIV lipodystrophy syndrome and may be due to an inability to

268 ether these changes have been termed the HIV-lipodystrophy syndrome, which is estimated to affect a m

269 e metabolic disturbances associated with HIV lipodystrophy syndrome.

270 Lipodystrophy syndromes are also associated with increas

271 HIV lipodystrophy and other lipodystrophy syndromes are characterized by extensive l

272 or 1 have been described linked to different lipodystrophy syndromes.

273 but tended to be higher in patients with HIV lipodystrophy than in healthy controls after a large tes

274 Although ATMs are even more abundant in lipodystrophy than in obesity, they have distinct phenot

275 iew addresses a syndrome of dyslipidemia and lipodystrophy that has emerged in HIV-infected patients

276 a fat-specific KO of dicer develop a form of lipodystrophy that is characterized by loss of intra-abd

277 drug-induced liver injury and depression or lipodystrophy) that led to discontinuation.

278 ct insulin sensitivity, as observed in human lipodystrophy, through reduced levels of adipocyte-deriv

279 signaling in a diabetic model of generalized lipodystrophy to analyze its effects on glucose metaboli

280 ransgenic (Tg) mice, an established model of lipodystrophy, to ask this question.

281 a polygenic contribution to familial partial lipodystrophy type 1, a severe form of insulin resistanc

282 Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is a recessive disorder fea

283 herited form is Berardinelli-Seip Congenital Lipodystrophy Type 2, associated with mutations in the B

284 reserved in mice with congenital generalized lipodystrophy type 3.

285 T occurs in mice with congenital generalized lipodystrophy type 4, whereas both rMAT and cMAT are pre

286 roups, and HGP was 2-fold higher in INSR and lipodystrophy versus type 2 diabetes and obesity (P < 0.

287 We showed that another mouse model of lipodystrophy was hypertensive, ruling out the lipodystr

288 Investigator-reported lipodystrophy was less common in the tenofovir DF group

289 Clinical and subclinical lipodystrophy was not noted in those younger than 5 year

290 However, fat redistribution (lipodystrophy) was recognized recently as a metabolic si

291 ight into how altered AGPAT2 activity causes lipodystrophy, we examined the effect of knockdown of AG

292 arboring pathogenic mutations known to cause lipodystrophy were also generated and characterized.

293 Four had a clinical diagnosis of lipodystrophy, whereas the remaining had no documented c

294 -1c mice develop a syndrome resembling human lipodystrophy, which includes a loss of peripheral white

295 HSCT, the patient developed mild symptoms of lipodystrophy, which raised the suspicion of a PRAAS.

296 Mr B, a 39-year-old man with HIV-associated lipodystrophy whose facial changes are a cause of signif

297 Efforts to ameliorate NASH in lipodystrophies with pharmacologic agents have met with

298 First described in 1907 as an intestinal lipodystrophy with histological finding of vacuoles in t

299 ion in adipose tissue can lead a syndrome of lipodystrophy with metabolic syndrome and cardiovascular

300 phy (fld) mouse is an exception, as there is lipodystrophy without a fatty liver.